Iatrogenic Atrial Septal Defect Study (iASD)

  • End date
    May 6, 2023
  • participants needed
  • sponsor
    Henry Ford Health System
Updated on 25 January 2021
mitral regurgitation
closure of atrial septal defect


This is an open-label, randomized, controlled trial of iatrogenic atrial septal defect closure with the an atrial septal occluder versus usual care observation in patients post-mitral valve intervention requiring large bore transspetal access.


This study is an open label, prospective, multicenter, non-randomized single-arm study to evaluate the safety and efficacy of the closing iatrogenic atrial septal defects in patients undergoing transcatheter mitral valve procedures using large sheaths.

A maximum of 5 Clinical Sites (referred to as "Sites" in the remainder of this document) in the U.S. Two hundred and ten patients will be enrolled in this study. The patients will randomized 1:2 device: control. The anticipated accrual rate is approximately 20 Subjects per month for a total accrual period of approximately 12-18 months.

Patients may be enrolled into the study provided all inclusion and no exclusion criteria are met as specified in Section 4. Subjects will be evaluated through hospital discharge and return for follow-up visits at 30 days, 6 months, and 12 months.

Condition Atrial septal defect
Treatment atrial septal defect closure
Clinical Study IdentifierNCT04395027
SponsorHenry Ford Health System
Last Modified on25 January 2021


Yes No Not Sure

Inclusion Criteria

Age 18 at the time of informed consent signature
Capable of complying with Protocol requirements, including follow-up
An Informed Consent Form signed by Subject or legal representative
Patient has had successful reduction of mitral regurgitation to at most moderate regurgitation post-mitral-clip

Exclusion Criteria

Remaining mitral regurgitation of moderate-severe
Subject unable or unwilling to provide informed consent
Concomitant severe aortic valve disease
Pregnancy or intent to become pregnant
Life expectancy < 1 year
Active bleeding
Inability to follow up with 6-month timepoint due logistical concerns
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note